More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$3.17B
EPS
-2.29
P/E ratio
--
Price to sales
0.21
Dividend yield
--
Beta
0.306207
Previous close
$8.42
Today's open
$8.39
Day's range
$8.21 - $8.48
52 week range
$4.33 - $9.04
show more
CEO
Thomas J. Appio
Employees
20300
Headquarters
Laval, QC
Exchange
New York Stock Exchange
Shares outstanding
374266716
Issue type
Common Stock
Healthcare
Pharmaceuticals
Here's Why Bausch Health (BHC) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks Investment Research • Nov 12, 2026

Bausch Health's Gastroenterology Business, Salix, to Present New Data on Cirrhosis Trends and Severe Alcohol-Associated Hepatitis at The Liver Meeting® 2026
LAVAL, QC, Nov. 6, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, will present a research poster at the American Association for the Study of Liver Diseases' The Liver Meeting® 2026, November 5–9 in Denver, Colorado. The study highlights the substantial mortality and rehospitalization among patients hospitalized with severe alcohol-associated hepatitis (AH).
PRNewsWire • Nov 6, 2026

BHC Q3 Earnings Call Highlights Raised Outlook, Xifaxan Risks
Bausch Health Companies Inc. BHC emphasized sustained operational growth, stronger cash generation and improved financial flexibility during its third-quarter 2026 earnings call. Management raised its full-year guidance while outlining anticipated headwinds from Xifaxan pricing changes and inventory adjustments.
Zacks Investment Research • Nov 4, 2026

Is Bausch Health (BHC) Stock Outpacing Its Medical Peers This Year?
Here is how Bausch Health (BHC) and Bausch + Lomb (BLCO) have performed compared to their sector so far this year.
Zacks Investment Research • Nov 3, 2026

Bausch Health Companies Inc. (BHC) Q3 2026 Earnings Call Transcript
Bausch Health Companies Inc. ( BHC ) Q3 2026 Earnings Call October 28, 2026 5:00 PM EDT Company Participants Garen Sarafian Thomas Appio - CEO & Director Jean-Jacques Charhon - Executive VP & CFO Conference Call Participants Umer Raffat - Evercore ISI Institutional Equities, Research Division Douglas Miehm - RBC Capital Markets, Research Division Presentation Operator Greetings, and welcome to the Bausch Health Third Quarter 2026 Earnings Conference Call. As a reminder, this conference is being recorded.
Seeking Alpha • Oct 29, 2026

BHC Q3 Earnings Beat on Salix Growth, Stock Gains 9% as Outlook Rises
Bausch Health shares jump 9% as Q3 earnings top estimates, driven by Xifaxan-led Salix growth, improved profitability and raised 2026 guidance.
Zacks Investment Research • Oct 29, 2026

What Bausch Health Cos (BHC) Said on Its Q3 Earnings Call
Bausch Health Cos NYSE: BHC raised its full-year 2026 outlook for the second consecutive quarter after reporting third-quarter growth across its operating segments, led by Salix and supported by international operations and Solta Medical.
MarketBeat • Oct 29, 2026

BAUSCH HEALTH ANNOUNCES THIRD QUARTER 2026 RESULTS, RAISES GUIDANCE
Third Quarter Consolidated Revenues of $2.94 billion, up 10% on a Reported basis and 8% on an Organic1 basis over the prior year period GAAP Net Income Attributable to Bausch Health of $436 million and GAAP Net Income of $446 million GAAP Earnings per Diluted Share Attributable to Bausch Health of $1.15 compared to $0.48 in the prior year period; Adjusted Earnings per Diluted Share1 of $1.77 compared to $1.16 in the prior year period, an increase of 53% Consolidated Adjusted EBITDA Attributable to Bausch Health1 of $1,305 million, up 32% over the prior year period BAUSCH HEALTH EXCLUDING BAUSCH + LOMB THIRD QUARTER 2026 RESULTS Delivered fourteenth consecutive quarter of year-over-year Revenue and Adjusted EBITDA1 growth, with 12% Reported and 8% Organic Revenue1 growth and 32% Adjusted EBITDA1 growth Net Income increased $205 million over the prior year Generated $581 million in Cash Provided by Operating Activities and $539 million in Adjusted Cash Flows from Operations1 Raising full year 2026 Revenue, Adjusted EBITDA1, and Adjusted Cash Flows from Operations1 guidance LAVAL, QC, Oct. 28, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its third quarter 2026 financial results and other key updates from the quarter. "Bausch Health, excluding Bausch + Lomb, delivered another solid quarter, marking fourteen consecutive quarters of year-over-year Revenue and Adjusted EBITDA growth.
PRNewsWire • Oct 28, 2026

Bausch Health (BHC) Surpasses Q3 Earnings and Revenue Estimates
Bausch Health (BHC) came out with quarterly earnings of $1.77 per share, beating the Zacks Consensus Estimate of $1.08 per share. This compares to earnings of $1.16 per share a year ago.
Zacks Investment Research • Oct 29, 2026

Bausch (BHC) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Bausch (BHC) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks Investment Research • Oct 29, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Bausch Health Companies Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.